[{"id":"ba15135a-7176-4f0e-a8cc-e6c040cf6509","acronym":"","url":"https://clinicaltrials.gov/study/NCT04574583","created_at":"2021-01-18T21:50:28.241Z","updated_at":"2025-02-25T17:00:40.932Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta \"Trap\"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","source_id_and_acronym":"NCT04574583","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • SX-682 • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 02/07/2023","primary_completion_date":" 02/07/2023","study_txt":" Completion: 05/19/2023","study_completion_date":" 05/19/2023","last_update_posted":"2025-02-03"},{"id":"f86dd180-9964-44e8-9f7d-13e77891a73a","acronym":"STOPTRAFFIC-1","url":"https://clinicaltrials.gov/study/NCT04599140","created_at":"2021-02-21T15:52:40.898Z","updated_at":"2025-02-25T14:29:40.279Z","phase":"Phase 1/2","brief_title":"SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial","source_id_and_acronym":"NCT04599140 - STOPTRAFFIC-1","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • CD8 • CD4 • CD69 • IRF2","pipe":"","alterations":" ","tags":["BRAF • CD8 • CD4 • CD69 • IRF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • SX-682"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/14/2020","start_date":" 10/14/2020","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-01-17"},{"id":"74a856b5-259a-4d5c-9166-0007d61a1cb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05570825","created_at":"2022-10-07T15:08:08.992Z","updated_at":"2024-07-02T16:35:05.631Z","phase":"Phase 2","brief_title":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05570825","lead_sponsor":"University of Washington","biomarkers":" PD-L1 • ALK • RET • ROS1","pipe":" | ","alterations":" PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["PD-L1 • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/06/2023","start_date":" 04/06/2023","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-05-07"},{"id":"52cec249-3dea-47ff-af14-c5976f1922da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05604560","created_at":"2022-11-03T14:56:55.660Z","updated_at":"2024-07-02T16:35:14.598Z","phase":"Phase 2","brief_title":"A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer","source_id_and_acronym":"NCT05604560","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TNFRSF9 • GZMB","pipe":"","alterations":" ","tags":["TNFRSF9 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • SX-682"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/08/2023","start_date":" 11/08/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-15"},{"id":"dafa2925-32f3-4c57-916b-ccb5ee13aa7f","acronym":"FRIDA","url":"https://clinicaltrials.gov/study/NCT02370238","created_at":"2021-01-18T11:17:27.837Z","updated_at":"2024-07-02T16:36:03.814Z","phase":"Phase 2","brief_title":"A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02370238 - FRIDA","lead_sponsor":"Dompé Farmaceutici S.p.A","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • reparixin (DF 1681Y)"],"overall_status":"Completed","enrollment":" Enrollment 194","initiation":"Initiation: 07/29/2015","start_date":" 07/29/2015","primary_txt":" Primary completion: 02/20/2019","primary_completion_date":" 02/20/2019","study_txt":" Completion: 03/23/2020","study_completion_date":" 03/23/2020","last_update_posted":"2022-09-16"},{"id":"cc6777a2-fbfc-48e1-b267-86384bf3d7ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03473925","created_at":"2021-01-18T17:07:13.286Z","updated_at":"2024-07-02T16:36:08.140Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)","source_id_and_acronym":"NCT03473925","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • navarixin (MK-7123)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 04/10/2018","start_date":" 04/10/2018","primary_txt":" Primary completion: 05/19/2021","primary_completion_date":" 05/19/2021","study_txt":" Completion: 05/19/2021","study_completion_date":" 05/19/2021","last_update_posted":"2022-06-29"},{"id":"d4991b18-5406-47c3-b13e-fa583d6baff0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02001974","created_at":"2021-01-18T09:08:28.016Z","updated_at":"2024-07-02T16:36:23.962Z","phase":"Phase 1","brief_title":"Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT02001974","lead_sponsor":"Dompé Farmaceutici S.p.A","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • reparixin (DF 1681Y)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 02/27/2012","start_date":" 02/27/2012","primary_txt":" Primary completion: 06/25/2014","primary_completion_date":" 06/25/2014","study_txt":" Completion: 01/15/2015","study_completion_date":" 01/15/2015","last_update_posted":"2021-09-27"}]